Recursion Pharmaceuticals (RXRX) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Is BPMC or RXRX more profitable?

Blueprint Medicines has a net margin of -27.70% compared to Recursion Pharmaceuticals' net margin of -961.32%. Blueprint Medicines' return on equity of -64.60% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-27.70%	-64.60%	-17.22%
Recursion Pharmaceuticals	-961.32%	-74.70%	-54.02%

Do analysts recommend BPMC or RXRX?

Blueprint Medicines presently has a consensus price target of $128.25, indicating a potential downside of 0.12%. Recursion Pharmaceuticals has a consensus price target of $7.00, indicating a potential upside of 30.60%. Given Recursion Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.24
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Do insiders & institutionals believe in BPMC or RXRX?

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 4.2% of Blueprint Medicines shares are owned by insiders. Comparatively, 8.4% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Which has better earnings and valuation, BPMC or RXRX?

Blueprint Medicines has higher revenue and earnings than Recursion Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$508.82M	16.30	-$67.09M	-$2.47	-51.98
Recursion Pharmaceuticals	$58.84M	37.03	-$463.66M	-$1.77	-3.03

Does the media refer more to BPMC or RXRX?

In the previous week, Recursion Pharmaceuticals had 12 more articles in the media than Blueprint Medicines. MarketBeat recorded 18 mentions for Recursion Pharmaceuticals and 6 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.68 beat Recursion Pharmaceuticals' score of 0.49 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Recursion Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk & volatility, BPMC or RXRX?

Blueprint Medicines has a beta of 0.89, suggesting that its share price is 11% less volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the S&P 500.

Summary

Recursion Pharmaceuticals beats Blueprint Medicines on 9 of the 17 factors compared between the two stocks.